Read by QxMD icon Read

Cancer Biomarkers: Section A of Disease Markers

Shu-Jian Chang, Xiao-Song Ge, Zhen-Yu Xu, Xiao-Wei Qi, Xiao-Ping Chen
BACKGROUND: Adjuvant chemotherapy plays important role in the comprehensive treatment of patients with stage III colorectal cancer. However, there is few molecular markers for predicting the therapeutic effect. OBJECTIVE: To identify factors that could predict adjuvant chemotherapy benefits in patients with stage III colorectal cancer. METHODS: The medical records of 294 patients were reviewed and analyzed using the Kaplan-Meier method and Cox analysis...
March 6, 2018: Cancer Biomarkers: Section A of Disease Markers
Yakup Bozkaya, Nuriye Yıldırım Özdemir, Sevilay Sezer, Osman Köstek, Nebi Serkan Demirci, Ozan Yazıcı, Gökmen Umut Erdem, Tülay Eren, Nurullah Zengin
BACKGROUND: The potential prognostic value of survivin is variably reported depending on the gastric cancer. OBJECTIVE: Evaluation of the prognostic and predictive significance of serum survivin and its relation with survival and treatment response rates in patients with locally advanced gastric cancer (LAGC). METHODS: Serum samples were prospectively collected from 50 patients with newly diagnosed LAGC. Serum samples of 32 healthy subjects were also collected as control groups for survivin levels...
March 5, 2018: Cancer Biomarkers: Section A of Disease Markers
Runhua Feng, Maneesh K Beeharry, Sheng Lu, Birendra K Sah, Fei Yuan, Min Yan, Bingya Liu, Chen Li, Zhenggang Zhu
BACKGROUND: miR-126 functions as a tumor suppressor in gastric cancer (GC), however, the clinical significance of serum miR-126 in GC remains unclear. OBJECTIVE: To investigate the associations of serum miR-126 level with the clinicopathological characteristics and prognosis of GC patients. METHODS: Quantitative real-time polymerase chain reaction was performed to examine the expression levels of miR-126 in 338 GC patients' tissues and sera, and 50 healthy controls' sera...
March 5, 2018: Cancer Biomarkers: Section A of Disease Markers
Grażyna Janikowska, Tomasz Janikowski, Alina Pyka-Paj K, Urszula Mazurek, Marcin Janikowski, Maciej Gonciarz, Zbigniew Lorenc
BACKGROUNDS: Colorectal cancer is the third most common cancer in economically developed countries. Molecular studies and, in particular, gene expression have contributed to advances in the diagnosis and treatment of many cancers. Genes can be molecular and therapeutic markers, but because of the large molecular diversity in colorectal cancer the knowledge is not yet fully established. Probably one of the most crucial processes during early cancer development is inflammation. The inflammatory response in the tumor is an important indicator of molecular etiology and later of cancer progression...
March 2, 2018: Cancer Biomarkers: Section A of Disease Markers
Tao Guo, Guobiao Pan
BACKGROUND: Accumulating studies have reported the abnormal expression of microRNA-136 (miR-136) in numerous types of human cancer, and its involvement in cancer initiation and progression. However, there are no investigations of miR-136 in osteosarcoma (OS). OBJECTIVE: To explore the expression pattern, clinical significance and potential roles of miR-136 in OS. METHODS: miR-136 expression in clinical OS tissues and human OS cell lines were detected by qPCR, and its associations with clinicopathological characteristics of OS patients were statistically analyzed...
March 2, 2018: Cancer Biomarkers: Section A of Disease Markers
Xin Zhou, Jing Wang, Jun Xia, Feng Cheng, Jingjue Mao, Jianwei Zhu, Hongfeng Guo
BACKGROUND: The neutrophil-to-lymphocyte ratio (NLR) at diagnosis has been identified as an independent prognostic marker in several malignancies. Recently, a few studies have reported that an elevated pretreatment NLR is associated with poor survival among multiple myeloma (MM) patients. However, the role of NLR at diagnosis in patients with MM treated with regimens containing bortezomib has been less explored. OBJECTIVE: We aimed to investigate the relationships between NLR and overall survival (OS) in newly diagnosed patients receiving bortezomib-based therapy for MM...
March 2, 2018: Cancer Biomarkers: Section A of Disease Markers
Kyu Young Choi, Jin Hwan Kim, Il Seok Park, Young Soo Rho, Gee Hwan Kwon, Dong Jin Lee
BACKGROUND: Cervical lymph node metastases (LNM) in papillary thyroid carcinomas (PTCs) are common and develop in approximately 30-80% of PTCs. The presence of cervical LNM significantly increases the rate of locoregional recurrence in PTCs. OBJECTIVE: To search for predictive gene signatures for nodal metastasis in PTCs. METHODS: We used unsupervised clustering with unbiased manner to compare molecular profiles between PTCs with nodal metastasis and PTCs without nodal metastasis using mRNA-seq of TCGA data...
March 1, 2018: Cancer Biomarkers: Section A of Disease Markers
Guoqing Duan, Su Hou, Jianjun Ji, Bin Deng
Sclareol (sclarcol) is an organic compound extracted from sage clary plants. Recent study has showed its anti-tumor effects against breast cancer, gastric carcinoma, osteosarcoma and colorectal cancer. However, its exact mechanisms in inhibiting tumor growth remain unknown. This study thus observed the effect of sclareol on the proliferation of osteosarcoma cells, in an attempt to investigate the role of sclarcol on osteosarcoma growth. MG63 osteosarcoma cell was treated with different concentrations of sclarcol...
March 1, 2018: Cancer Biomarkers: Section A of Disease Markers
Maryam Khorasani, Ladan Teimoori-Toolabi, Taghi Naserpour Farivar, Mojgan Asgari, Maryam Abolhasani, Hossein Shahrokh, Ali Afkar, Elham Kalantari, Amir Peymani, Reza Mahdian
BACKGROUND: Prostate cancer (PCa) is the second most common cancer in men worldwide. Currently, prostate-specific antigen (PSA) test and digital rectal exam are the main screening tests used for PCa diagnosis. However, due to the low specificity of these tests, new alternative biomarkers such as deregulated RNAs and microRNAs have been implemented. OBJECTIVES: Aberrant expression of small heterodimer partner gene (SHP, NR0B2) and mir-141 are reported in various cancers...
February 28, 2018: Cancer Biomarkers: Section A of Disease Markers
Xu Wang, Xiaochang Zhang, Lina Jin, Zhiguang Yang, Wei Li, Jiuwei Cui
OBJECTIVE: Early detection and diagnosis of lung cancer remain challenging but would improve patient prognosis. The goal of this study is to develop a model to estimate the risk of lung cancer for a given individual. METHODS: We conducted a case-control study to develop a predictive model to identify individuals at high risk for lung cancer. Clinical data from 500 lung cancer patients and 500 population-based age- and gender-matched controls were used to develop and evaluate the model...
February 28, 2018: Cancer Biomarkers: Section A of Disease Markers
Qi Chen, Hong Zhang
Ovarian cancer has the highest mortality rate among gynecological malignancies, presenting a major threat to women's life and health. It is essential to study the mechanisms of drug resistance to chemotherapy to identify ways to enhance drug-sensitivity. In recent years, many studies have shown that Smac/DIABLO is closely related to tumor drug resistance. Smac/DIABLO expression is markedly different between drug-resistant and chemo sensitive tumor cells. Up-regulation of Smac/DIABLO has been shown to increase tumor cell chemotherapy sensitivity...
February 28, 2018: Cancer Biomarkers: Section A of Disease Markers
Libin Wang, Feng Wang, Li Na, Jingjing Yu, Liya Huang, Zhi-Qiang Meng, Zhen Chen, Hao Chen, Liu-Lu Ming, Yong-Qiang Hua
BACKGROUND: Recent study revealed that abnormal long noncoding RNAs (lncRNAs) expression are association with chemotherapy resistance of pancreatic ductal adenocarcinoma (PDAC). OBJECTIVE: The present study was aimed to investigate the effects of lncRNA AB209630 expression for gemcitabine resistance in PDAC cells. METHODS: In the study, increased expression of lncRNA AB209630 could suppress cell proliferation and cell colony formation ability in gemcitabine resistance cells of PDAC...
February 28, 2018: Cancer Biomarkers: Section A of Disease Markers
Qianping Zhou, Lanshan Huang, Yongyao Gu, Huiping Lu, Zhenbo Feng
BACKGROUND: Molecular target therapy has become a hot spot in cancer treatment, finding effective targets for diffuse large B cell lymphoma (DLBCL) is an urgent problem. OBJECTIVE: To detect the expression level of C-C motif chemokine ligand 18 (CCL18) in DLBCL and clarify its potential role in the progression of DLBCL. METHODS: Gene expression datas of DLBCL were obtained from TCGA and GEO databases. The relationship between CCL18 and clinicopathologic information of DLBCL was assessed using meta-analysis method...
February 9, 2018: Cancer Biomarkers: Section A of Disease Markers
Jianxia Hu, Xiaoyi Liu, Jingwei Chi, Kui Che, Yan Feng, Shihua Zhao, Zhongchao Wang, Yangang Wang
BACKGROUND: Epidemiological data have revealed that colorectal cancer (CRC) risk is increased in patients with Metabolic syndrome. OBJECTIVE: To explore the expressions of IGF-1, ERK, GLUT4, IRS-1 in MS patients with CRC and their associations with the clinical characteristics of CRC. METHODS: We investigated the expressions of IGF-1, ERK, GLUT4 and IRS-1 in greater omental adipose tissues of 168 MS patients with/without CRC, 85 CRC patients without MS and 98 healthy controls by RT-PCR, and analyzed the relationships between their expressions and clinical characteristics of CRC...
February 9, 2018: Cancer Biomarkers: Section A of Disease Markers
Li-Xia Zhong, Jun-Hua Nie, Jia Liu, Li-Zhu Lin
BACKGROUND: Aplysia ras homology member I/ARHI is known as ovarian cancer suppressor gene and potential inhibitor of signal transducer and activator of transcription 3/STAT3 signaling. Resveratrol suppresses growth and STAT3 activation of ovarian cancer cells, while its influence in ARHI expression remains unknown. OBJECTIVE: The current study aims to elucidate the status of ARHI expression and its relevance with growth suppression and STAT3 inactivation of resveratrol-treated cells...
February 9, 2018: Cancer Biomarkers: Section A of Disease Markers
Fei Qiu, Wei Gao, Bin Wang
Colorectal cancer (CRC) is one of the most common malignant tumors in digestive tract. Previous study found close correlation between insulin-like growth factor binding proteins (IGFBPs) and occurrence of multiple tumors. This study aims to analyze the effects of IGFBP6 on the apoptosis and migration of tumor cells, and to investigate underlying mechanism. HCT-116 or SW480 cell was cultured with 1.0 mg/l, 10 mg/l and 100 mg/l IGFBP-6. MTT assay was employed to test the proliferation activity of tumor cells after differential treatment...
February 2, 2018: Cancer Biomarkers: Section A of Disease Markers
Jinhua Yan, Guohe Wu, Jianlan Chen, Lifang Xiong, Guoan Chen, Ping Li
BACKGROUND: Circulating microRNAs (miRNAs) play an essential role in the development and progression of acute myeloid leukemia (AML). However, the clinical value of serum miR-217 in AML remained poorly known. OBJECTIVE: This study aimed to explore the clinical significance of serum miR-217 in AML. METHODS: Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was performed to detect miR-217 levels in the blood samples obtained from 89 AML patients and 60 healthy controls...
January 29, 2018: Cancer Biomarkers: Section A of Disease Markers
Jun Ma, Kaiming Wu, Kuanzhi Liu, Rong Miao
OBJECTIVE: To explore the ability of MALAT1 to influence non-small cell lung cancer (NSCLC) A549 cells in vitro and tumor xenograft growth in vivo by modulating autophagy. METHODS: LncRNA MALAT-1 in normal HBE cells and human NSCLC cells was measured. A549 cells were treated with si-MALAT-1, negative control and si-MALAT-1 + rapamycin. The mRNA levels of MALAT-1, P62 and LC3 was determined by the qRT-PCR and the protein levels of autophagy-related proteins by the western blotting...
January 29, 2018: Cancer Biomarkers: Section A of Disease Markers
Ali Dianatpour, Sepideh Faramarzi, Lobat Geranpayeh, Reza Mirfakhraie, Elahe Motevaseli, Soudeh Ghafouri-Fard
Long non-coding RNAs (lncRNA) constitute a significant percentage of RNAs with no translation to proteins. Their participation in fundamental aspects of cell physiology as well as their dysregulation in a number of pathologic conditions such as cancer have been documented. Among lncRNAs is actin filament associated protein 1 antisense RNA1 (AFAP1-AS1) whose elevated expression levels have been demonstrated in different cancers. In the in the present study we evaluated expression levels of AFAP1-AS1 and its antisense protein coding gene AFAP1 in breast cancer samples compare with adjacent non-cancerous tissues (ANCTs) as well as breast cancer cell lines with special focus on the assessment of the association between their transcript levels and patients' clinicopathological data...
January 29, 2018: Cancer Biomarkers: Section A of Disease Markers
Dong Wang, Juan Zhou, Jihua Zheng, Jiang Zhang, Yaoming Chen, Wen Li, Ruizhi Wang
BACKGROUND: Cisplatin-based concurrent chemoradiotherapy is recommended for nasopharyngeal carcinoma (NPC) at advanced stages. Excision repair cross-complementation group 1 (ERCC1) plays an important function in the repair of DNA damage that is a critical process of chemo- and radiotherapy. OBJECTIVE: This study aimed to investigate the clinical significance of ERCC1 expression in NPC treated with cisplatin-based concurrent chemoradiotherapy in locoregionally advanced NPC...
January 29, 2018: Cancer Biomarkers: Section A of Disease Markers
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"